Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026 ...
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a ...
Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research ...
The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.
Belief BioMed (BBM) today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially ...
New research shows epigenetic silencing may limit durability of AAV gene therapy in haemophilia by reducing long term transgene expression in liver cells.
Applied Biopharm Consulting Ltd has been awarded an Intellectual Property (IP) Start Grant from the Local Enterprise Office under Enterprise Ireland’s IP Strategy initiative. The grant will support ...
Vietnam Investment Review on MSN
Belief BioMed gains Macao approval for hemophilia B gene therapy
SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical ...
Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ...
Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate AS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results